

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : AUGUSTYN, et al.

Serial No.: 10/565,515

Art Unit: 3771

Filing Date: January 23, 2006

Examiner: Ostrup, Clinton T.

For: MEDICAMENT DISPENSER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

This is filed concurrently with a Request for Continued Examination. The Commissioner is authorized to charge any fee due in connection with this filing, or credit any overpayment, to Deposit Account No. 07-1392.

**Amendment** is set forth here on **Page 2**.

**Amendment to Inventorship:**

Please amend the inventorship such that these people are the only named inventors:

Paul Rand  
Michael Davies  
Stephen Augustyn  
Stephen Harvey

The following individuals should be deleted:

Mark Palmer  
Alan Wilson

**REMARKS**

This is filed concurrently with a Request for Continued Examination and an Information Disclosure Statement.

Additionally, pursuant to 37 C.F.R. 1.48(b)(1), Applicants request amendment of inventorship and acknowledges that the deleted inventor's contribution is no longer being claimed in this application. In this instance, Mark Palmer and Alan Wilson are no longer inventors.

Respectfully Submitted,

/Robert J. Smith/  
Robert J. Smith  
Agent of Record  
Registration No. 40,820

Date: June 21, 2011

GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-9616  
Facsimile: (919) 483-7988